

Name : Mr. JASBIR KAUR

Lab No. : 283280068

A/c Status

P

Age: 50 Years

Ref By: Dr. SELF

Gender:

Male

Collected Received 30/6/2020 8:07:00AM

Reported

30/6/2020 11:23:02AM 30/6/2020 5:49:12PM

Report Status : Interim

Test Name	Results	Units	Bio. Ref. Interval
SWASTHFIT SUPER 4 PACKAGE			
LIVER & KIDNEY PANEL, SERUM (Spectrophotometry, Indirect ISE)			
Bilirubin Total	0.66	mg/dL	0.30 - 1.20
Bilirubin Direct	0.17	mg/dL	<0.30
Bilirubin Indirect	0.49	mg/dL	<1.10
AST (SGOT)	21	U/L	<50
ALT (SGPT)	15	U/L	<50
GGTP	15	U/L	<55
Alkaline Phosphatase (ALP)	76	U/L	30 - 120
Total Protein	7.10	g/dL	6.40 - 8.30
Albumin	4.16	g/dL	3.50 - 5.20
A : G Ratio	1.41		0.90 - 2.00
Urea	18.80	mg/dL	17.00 - 43.00
Creatinine	0.56	mg/dL	0.67 - 1.17



Page 1 of 14



Name : Mr. JASBIR KAUR	Collected : 30/6/2020 8:07:00AM
Lab No. : 283280068 Age: 50 Years Gender: Male	Received : 30/6/2020 11:23:02AM  Reported : 30/6/2020 5:49:12PM
A/c Status : P Ref By : Dr. SELF	Report Status : Interim

Results 3.78	<b>Units</b> mg/dL	<b>Bio. Ref. Interval</b> 3.50 - 7.20
0.40	-	
9.16	mg/dL	8.80 - 10.60
4.30	mg/dL	2.40 - 4.40
132.49	mEq/L	136.00 - 146.00
4.36	mEq/L	3.50 - 5.10
98.97	mEq/L	101.00 - 109.00
	3.78 9.16 4.30 132.49 4.36	<ul> <li>3.78 mg/dL</li> <li>9.16 mg/dL</li> <li>4.30 mg/dL</li> <li>132.49 mEq/L</li> <li>4.36 mEq/L</li> </ul>





Name : Mr. JASBIR KAUR

Lab No.

A/c Status

283280068 Age: 50 Years

Ref By: Dr. SELF

Gender: Male

Collected Received : 30/6/2020 8:07:00AM

Reported

30/6/2020 11:23:02AM 30/6/2020 5:49:14PM

Report Status : Interim

Test Name	Results	Units	Bio. Ref. Interval
COMPLETE BLOOD COUNT;CBC (Electrical Impedance & Flow)			
Hemoglobin	14.20	g/dL	13.00 - 17.00
Packed Cell Volume (PCV)	41.80	%	40.00 - 50.00
RBC Count	4.97	mill/mm3	4.50 - 5.50
MCV	84.10	fL	80.00 - 100.00
MCH	28.60	pg	27.00 - 32.00
MCHC	34.00	g/dL	32.00 - 35.00
Red Cell Distribution Width (RDW)	13.60	%	11.50 - 14.50
Total Leukocyte Count (TLC)	4.71	thou/mm3	4.00 - 10.00
Differential Leucocyte Count (DLC)			
Segmented Neutrophils	47.90	%	40.00 - 80.00
Lymphocytes	39.90	%	20.00 - 40.00
Monocytes	9.30	%	2.00 - 10.00
Eosinophils	2.30	%	1.00 - 6.00
Basophils	0.60	%	<2.00
Absolute Leucocyte Count			
Neutrophils	2.26	thou/mm3	2.00 - 7.00
Lymphocytes	1.88	thou/mm3	1.00 - 3.00
Monocytes	0.44	thou/mm3	0.20 - 1.00
Eosinophils	0.11	thou/mm3	0.02 - 0.50
Basophils	0.03	thou/mm3	0.01 - 0.10
Platelet Count	292.0	thou/mm3	150.00 - 450.00



Page 3 of 14



Name ... Mr. JASBIR KAUR

283280068

Age: 50 Years

Ref By: Dr. SELF

On Lad PathLabs 1

Male

Collected Received Reported : 30/6/2020 8:07:00AM : 30/6/2020 11:23:02AM

: 30/6/2020 5:49:14PM

Report Status : Interim

Test Name	Results	Units	Bio. Ref. Interval
Mean Platelet Volume (MPV)	11.50	fL	6.50 - 12.00

Gender:

## Note

Lab No.

A/c Status

- As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood
- 2. Test conducted on EDTA whole blood



Reported

30/6/2020 5:49:16PM



L38 - FPSC SHARANPUR CHOWK DHERADUN 78, Arhat Bazar, Near Shivaji Dharamshal Saharanpur Road, Dehradun-248001

Name Mr. JASBIR KAUR Collected : 30/6/2020 8:07:00AM Received : 30/6/2020 11:23:02AM 283280068 Lab No. Age: 50 Years Gender: Male

A/c Status Ref By: Dr. SELF **Report Status** Interim

Test Name	Results	Units	Bio. Ref. Interval
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD (HPLC)			
HbA1c	5.2	%	
Estimated average glucose (eAG)	103	mg/dL	

#### Interpretation

As per American	n Diabetes Association (ADA)
Reference Group	HbA1c in %
Non diabetic adults >=18 years	4.0 - 5.6
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	< 7.0

## **Note**

- 1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled
- 2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate
- 3. Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the A1C result does not correlate with the patient's blood glucose levels
- 4. In patients with HbA1c level between 7-8%, Glycemark (1,5 Anhydroglucitol) test may be done to identify those with more frequent and extreme hyperglycemic excursions

## Comments

HbA1C reflects average glycemia over approximately 3 months, the test is the major tool for assessing glycemic control and has strong predictive value for diabetes complications. Thus, HbA1C testing should be performed routinely in all patients with diabetes - at initial assessment and as part of continuing care.



Page 5 of 14



Name Mr. JASBIR KAUR

Lab No.

A/c Status

283280068

als De Lat Parkitals De Lat Parkitals De

Age: 50 Years

Dr. SELF

Ref By:

Gender: M

Male Received Reported

: 30/6/2020 8:07:00AM : 30/6/2020 11:23:02AM

: 30/6/2020 5:49:16PM

Report Status : Interim

Collected

Test Name Results Units Bio. Ref. Interval Measurement approximately every 3 months determines whether patients' glycemic targets have been

reached and maintained. The frequency of A1C testing should depend on the clinical situation, the treatment regimen, and the clinician's judgement.

# ADA Recommendations for HbA1c testing

- 1. Perform the A1C test at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control)
- Perform the A1C test quarterly in patients whose therapy has changed or who are not meeting glycemic goals

Factors that Interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements

Factors that affect interpretation of HbA1c Results: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c





Name Collected 30/6/2020 8:07:00AM : Mr. JASBIR KAUR 30/6/2020 11:23:02AM Received 283280068 Age: 50 Years Lab No. Gender: Male Reported 30/6/2020 5:49:18PM A/c Status Ref By: Dr. SELF **Report Status** Interim

Test Name	Results	Units	Bio. Ref. Interval
THYROID PROFILE,TOTAL, SERUM (ECLIA)			
T3, Total *	0.90	ng/mL	0.80 - 2.00
T4, Total *	10.24	ug/dL	5.10 - 14.10
TSH *	3.10	uIU/mL	0.27 - 4.20

## Note

- 1. TSH levels are subject to circadian variation, reaching peak levels between 2 4.a.m. and at a minimum between 6-10 pm. The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- 2. Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
- 3. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

# **Clinical Use**

- · Primary Hypothyroidism
- Hyperthyroidism
- · Hypothalamic Pituitary hypothyroidism
- Inappropriate TSH secretion
- Nonthyroidal illness
- Autoimmune thyroid disease
- · Pregnancy associated thyroid disorders
- · Thyroid dysfunction in infancy and early childhood

\* Not in NABL scope



Page 7 of 14



Name : Mr. JASBIR KAUR

Lab No. : 283280068

A/c Status

Age: 50 Years

Ref By: Dr. SELF

Male

Gender:

Received Reported 30/6/2020 8:07:00AM

: 30/6/2020 11:23:02AM : 30/6/2020 5:49:21PM

Report Status : Interim

Test Name	Results	Units	Bio. Ref. Interval
LIPID SCREEN, SERUM (Spectrophotometry)			
Cholesterol, Total	172.00	mg/dL	<200.00
Triglycerides	67.00	mg/dL	<150.00
HDL Cholesterol	55.93	mg/dL	>40.00
LDL Cholesterol, Calculated	102.67	mg/dL	<100.00
VLDL Cholesterol,Calculated	13.40	mg/dL	<30.00
Non-HDL Cholesterol	116	mg/dL	<130

## Interpretation

REMARKS	TOTAL CHOLESTEROL   in mg/dL	TRIGLYCERIDE   in mg/dL	LDL CHOLESTEROL   in mg/dL	NON HDL CHOLESTEROL     in mg/dL
Optimal	<200	<150	<100	<130
Above Optimal	   -		100-129	130 - 159
Borderline High	200-239	150-199	130-159	160 - 189
High	>=240	200-499	160-189	190 - 219
Very High	-	>=500	   >=190	>=220

## Note

- Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
- 2. NLA-2014 recommends a complete lipoprotein profile as the initial test for evaluating cholesterol.



Page 8 of 14



Name : Mr. JASBIR KAUR

Lab No.

Mr. JASBIR KAUR

Collected

: 30/6/2020 8:07:00AM

283280068 Age: 50 Years Gender: Male Received

30/6/2020 11:23:02AM 3 : 30/6/2020 5:49:21PM

A/c Status : P Ref By : Dr. SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

- Friedewald equation to calculate LDL cholesterol is most accurate when Triglyceride level is < 400 mg/dL. Measurement of Direct LDL cholesterol is recommended when Triglyceride level is > 400 mg/dL
- NLA-2014 identifies Non HDL Cholesterol(an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.
- 5. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved
- 6. Additional testing for Apolipoprotein B, hsCRP,Lp(a ) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

## Treatment Goals as per Lipid Association of India 2016

RISK CATEGORY	TREATMENT GOAL		CONSI	DER THERAPY
CATEGORY	LDL CHOLESTEROL (LDL-C)(mg/dL)	NON HDL CHLOESTEROL (NON HDL-C) (mg/dL)	LDL CHOLESTEROL (LDL-C)(mg/dL)	NON HDL CHLOESTEROL   (NON HDL-C) (mg/dL)
Very   High	<50		>=50	>=80   
High	<70	<100	>=70	>=100
Moderate	<100	<130	>=100	>=130
Low	<100	<130	>=130*	>=160*

<sup>\*</sup>In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months





Name : Mr. JASBIR KAUR

Lab No. 283280068 Age:

Age: 50 Years

Ref By:

Male

Received Reported : 30/6/2020 8:07:00AM

: 30/6/2020 11:23:02AM : 30/6/2020 5:49:23PM

Report Status : Interim

 Test Name
 Results
 Units
 Bio. Ref. Interval

 VITAMIN B12; CYANOCOBALAMIN, SERUM \*
 382.60
 pg/mL
 197.00 - 771.00

 (ECLIA)

Gender:

#### **Notes**

A/c Status

1. Interpretation of the result should be considered in relation to clinical circumstances.

Dr. SELF

- It is recommended to consider supplementary testing with plasma Methylmalonic acid (MMA) or
  plasma homocysteine levels to determine biochemical cobalamin deficiency in presence of clinical
  suspicion of deficiency but indeterminate levels. Homocysteine levels are more sensitive but MMA is
  more specific
- 3. The concentration of Vitamin B12 obtained with different assay methods cannot be used interchangeably due to differences in assay methods and reagent specificity

## Comments

Vitamin B12 performs many important functions in the body, but the most significant function is to act as co-enzyme for reducing ribonucleotides to deoxyribonucleotides, a step in the formation of genes. Inadequate dietary intake is not the commonest cause for cobalamine deficiency. The most common cause is malabsorption either due to atrophy of gastric mucosa or diseases of terminal ileum. Cobalamine deficiency leads to Megaloblastic anemia and demyelination of large nerve fibres of spinal cord. Normal body stores are sufficient to last for 3-6 years. Sources of Vitamin B12 are liver, shellfish, fish, meat, eggs, milk, cheese & yogurt.

## **Decreased Levels**

- Lack of Intrinsic factor: Total or partial gastrectomy, Atrophic gastritis, Intrinsic factor antibodies
- Malabsorption: Regional ileitis, resected bowel, Tropical Sprue, Celiac disease, pancreatic insufficiency, bacterial overgrowth & achlorhydria
- Loss of ingested vitamin B12: fish tapeworm
- · Dietary deficiency: Vegetarians
- Congenital disorders: Orotic aciduria & transcobalamine deficiency
- Increased demand: Pregnancy specially last trimester

## **Increased Levels**

Chronic renal failure, Congestive heart failure, Acute & Chronic Myeloid Leukemia, Polycythemia vera, Carcinomas with liver metastasis, Liver disease, Drug induced cholestasis & Protein malnutrition

\* Not in NABL scope



Page 10 of 14



Name : Mr. JASBIR KAUR

WIF. JASBIR KAUR

Ref By: Dr. SELF

283280068 Age: 50 Years

Male

Received Reported : 30/6/2020 8:07:00AM

: 30/6/2020 11:23:02AM : 30/6/2020 5:49:23PM

Report Status : Interim

 Test Name
 Results
 Units
 Bio. Ref. Interval

 VITAMIN D, 25 - HYDROXY, SERUM \*
 92.51
 nmol/L
 75.00 - 250.00

Gender:

(ECLIA)

Lab No.

A/c Status

### Interpretation

LEVEL	REFERENCE RANGE   IN nmol/L	COMMENTS
Deficient	< 50 	High risk for developing     bone disease
Insufficient     	   50-74 	Vitamin D concentration     which normalizes   Parathyroid hormone     concentration
Sufficient	75-250 	Optimal concentration     for maximal health benefit
Potential   intoxication	>250 	   High risk for toxic

## Note

- The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
- 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
- Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
- It shows seasonal variation, with values being 40-50% lower in winter than in summer.
- Levels vary with age and are increased in pregnancy.
- A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available

## Comments

Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

## **Decreased Levels**

\* Not in NABL scope



Page 11 of 14



Name : Mr. JASBIR KAUR

Lab No. : 283280068 Age: 50 Years

Ref By: Dr. SELF

Collected Received : 30/6/2020 8:07:00AM

Received : 30/6/2020 11:23:02AM Reported : 30/6/2020 5:49:23PM

Report Status : Interim

Test Name Results Units Bio. Ref. Interval

Male

Gender:

- Inadequate exposure to sunlight
- Dietary deficiency
- Vitamin D malabsorption
- Severe Hepatocellular disease
- Drugs like Anticonvulsants
- Nephrotic syndrome

# **Increased levels**

A/c Status

Vitamin D intoxication

\* Not in NABL scope



Page 12 of 14

Collected

30/6/2020 8:07:00AM



L38 - FPSC SHARANPUR CHOWK DHERADUN 78, Arhat Bazar, Near Shivaji Dharamshal Saharanpur Road, Dehradun-248001

Lab No.

Name Cod D: Mr. JASBIR KAUR Cod Do Av Political Do Av Political Do Av


: 283280068 Age: 50 Years Gender: Male Received : 30/6/2020 11:23:02AM
Reported : 30/6/2020 5:49:25PM

A/c Status : P Ref By : Dr. SELF Report Status : Interim

Test Name	Results	Units	Bio. Ref. Interval
URINE EXAMINATION, ROUTINE; URINE, R/E (Dipstick, Microscopy)			
Physical			
Colour	Light Yellow		Pale yellow
Specific Gravity	1.010		1.001 - 1.030
pH	6		5.0 - 8.0
Chemical			
Proteins	Negative		Negative
Glucose	Negative		Negative
Ketones	Negative		Negative
Bilirubin	Negative		Negative
Jrobilinogen	Negative		Negative
eucocyte Esterase	Negative		Negative
Nitrite	Negative		Negative
Microscopy			
R.B.C.	Negative		0.0 - 2.0 RBC/hpf
Pus Cells	0-1 WBC/HPF		0-5 WBC / hpf
Epithelial Cells	2-3 Epi Cells/hpf		0.0 - 5.0 Epi cells/hpf
Casts	None seen		None seen/Lpf
Crystals	None seen		None seen
Others	None seen		None seen



Page 13 of 14





Name Mr. JASBIR KAUR

283280068

Dr. And Prof. And Dr. And Prof. And Dr. And Prof. Collected

Received : 30 Reported : 30

: 30/6/2020 8:07:00AM : 30/6/2020 11:23:02AM : 30/6/2020 5:49:25PM

A/c Status : P Ref By : Dr. SELF R

Age: 50 Years

Report Status : Interim

Test Name Results Units Bio. Ref. Interval

Gender:

Dr Pritika Uniyal MD, Pathology Chief of Lab

Lab No.

Result/s to follow:

IMMUNOGLOBULIN IgE, SERUM

#### **IMPORTANT INSTRUCTIONS**

\*Test results released pertain to the specimen submitted.\*All test results are dependent on the quality of the sample received by the Laboratory.

\*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .\*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.\*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.\*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.\*Test results may show interlaboratory variations.\*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).\*Test results are not valid for medico legal purposes. \*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.

(#) Sample drawn from outside source.



Page 14 of 14